Cargando…

PB1851: EARLY DEATHS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY FROM A GENERAL HOSPITAL

Detalles Bibliográficos
Autores principales:	Yohannan, B., Cervoni-curet, F., Rios, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430407/ http://dx.doi.org/10.1097/01.HS9.0000850256.38535.1c

Ejemplares similares

PB1891: EARLY DEATH IN ACUTE PROMYELOCYTIC LEUKEMIA IN SOUTHERN TUNISIA
por: Koubaa, Asma, et al.
Publicado: (2023)

PB1842: EARLY DEATH IN NEWLY DIAGNOSED ADULT ACUTE MYELOID LEUKEMIA
por: Siala, N., et al.
Publicado: (2022)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB1803: EARLY DEATH IN ACUTE PROMYELOCYTIC LEUKEMIA: DEFINING HIGH RISK PATIENTS
por: `Ben Salah, M., et al.
Publicado: (2022)

PB1901: NOT ALL VARIANTS OF ACUTE PROMYELOCYTIC LEUKEMIAS ARE RESISTANT TO RETINOIDS.
por: Dandwani, Mehndi, et al.
Publicado: (2023)

PB1819: CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA IN SOUTHERN TUNISIA
por: kasser, O., et al.
Publicado: (2022)

PB1895: CHARACTERISTICS AND OUTCOME OF PEADIATRIC ACUTE PROMYELOCYTIC LEUKEMIA IN SOUTHERN TUNISIA
por: Koubaa, Asma, et al.
Publicado: (2023)

PB1802: ACUTE PROMYELOCYTIC LEUKEMIA AND THROMBOSIS: HOW TO IDENTIFY THE HIGH-RISK PATIENTS?
por: `Ben Salah, M., et al.
Publicado: (2022)

P1660: THROMBOSIS RISK IN PATIENTS WITH ACUTE LEUKEMIA (AL)
por: Yohannan, Binoy, et al.
Publicado: (2023)

PB1877: EFFECTS OF VENETOCLAX-BASED COMBINATIONS FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA IN CLINICAL SETTINGS
por: Park, Young Seob, et al.
Publicado: (2023)

PB2227: TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS INTO ACUTE PROMYELOCYTIC LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS OF CASE REPORTS
por: Găman, Mihnea-Alexandru
Publicado: (2023)

PB2135: TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

PB1816: CHEMOTHERAPY FREE APPROACH IN A PEDIATRIC PATIENT WITH VERY LATE CUTANEOUS RELAPSE OF ACUTE PROMYELOCYTIC LEUKEMIA.
por: Crisci, V., et al.
Publicado: (2022)

PB1796: DETERMINATION OF THE RELATIONSHIP BETWEEN NEXT GENERATION SEQUENCING AND FLOW CYTOMETRY RESULTS IN NEWLY DIAGNOSED ACUTE MYELOBLASTIC LEUKEMIA
por: Yavasoglu, I., et al.
Publicado: (2022)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

PB1954: PROGNOSTIC ANALYSIS OF GENE MUTATIONS ON TIME-TO-FIRST TREATMEN IN 93 NEWLY DIAGNOSED CHRONIC LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Xiang, Xixi, et al.
Publicado: (2023)

PB2017: YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A TUNISIAN SINGLE-CENTER EXPERIENCE
por: Kallel, F., et al.
Publicado: (2022)

PB2691: ARSENIC RETENTION IN TISSUES AND QUALITY OF LIFE IN PEDIATRIC ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ARSENICALS: A CROSS SECTIONAL STUDY
por: Wu, Chao, et al.
Publicado: (2023)

PB2577: INFECTIONS AND THEIR RELATIONSHIP WITH EARLY MORTALITY IN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA
por: Ontiveros-Austria, Juan Luis, et al.
Publicado: (2023)

PB2288: INCIDENCE OF NEWLY DIAGNOSED AGGRESSIVE NON-HODGKIN’S LYMPHOMA BEFORE AND DURING THE COVID-19 PANDEMIC IN ISRAEL - A SINGLE CENTER RETROSPECTIVE STUDY
por: Bronstein, Yotam, et al.
Publicado: (2023)

PB1846: ALTERATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UPDATED PROSPECTIVE ANALYSIS.
por: Stupakova, Z., et al.
Publicado: (2022)

PB1828: REALGAR (AS4S4), A TRADITIONAL CHINESE MEDICINE, INDUCES ACUTE PROMYELOCYTIC LEUKEMIA CELL DEATH VIA THE BCL-2/BAX/CYT-C/AIF SIGNALING PATHWAY IN VITRO
por: LI, Zonghong, et al.
Publicado: (2023)

PB2298: THE RELATIONSHIP BETWEEN PLATELET SPECIFIC ANTIBODIES AND THE SEVERITY OF NEWLY DIAGNOSED PEDIATRIC ITP
por: Dong, S.
Publicado: (2022)

PB2358: SIGNIFICANT INCREASE IN NEWLY DIAGNOSED HEMATOLOGICAL MALIGNANCIES FOLLOWING LOCKDOWN EASE IN CROATIA
por: Simunic, M., et al.
Publicado: (2022)

PB2212: ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM
por: Lee, Myung-Won, et al.
Publicado: (2023)

PB2311: LOW-DOSE PREDNISON AND ELTROMBOPAG COMBINATION AS FRONTLINE TREATMENT IN NEWLY DIAGNOSED ITP PATIENTS
por: Liu, S.-Y., et al.
Publicado: (2022)

PB2009: OPPORTUNITIES OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WITH DIALYSIS-DEPENDENT RENAL IMPAIRMENT
por: Kliuchagina, I., et al.
Publicado: (2022)

PB2136: THE VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PREDICTING THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Liu, Zhaoyun, et al.
Publicado: (2023)

PB2027: EFFICACY OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME WITH UNFAVORABLE IMMUNOPHENOTYPIC AND CYTOGENETIC PROGNOSIS.
por: Trubkina, Hanna, et al.
Publicado: (2023)

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
por: Jabbour, E., et al.
Publicado: (2022)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
por: Nuevo López, M. I., et al.
Publicado: (2022)

PB2684: QUALITY OF LIFE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO SUFFERED FROM RUSSIAN MILITARY AGGRESSION IN UKRAINE: A SINGLE CENTER EXPERIENCE
por: Lymanets, Tetiana, et al.
Publicado: (2023)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hughes, T., et al.
Publicado: (2022)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

PB2036: RISK AND PATTERN OF INFECTIONS IN NEWLY DIAGNOSED PATIENTS OF MULTIPLE MYELOMA VACCINATED UPFRONT AGAINST PNEUMOCOCCUS & INFLUENZA
por: VA, A., et al.
Publicado: (2022)

PB2297: THE PREDICTIVE VALUE OF PLATELET SPECIFIC ANTIBODIES FOR THE FIRST-LINE TREATMENT EFFECT IN NEWLY DIAGNOSED PEDIATRIC ITP
por: Dong, S.
Publicado: (2022)

PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE
por: Elsabah, H., et al.
Publicado: (2022)

PB2010: FIRST-LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES: A GLOBAL, RETROSPECTIVE OBSERVATIONAL COHORT STUDY
por: Zeidan, Amer M., et al.
Publicado: (2023)

PB1769: REAL WORLD DATA OUTCOMES IN A SINGLE MEXICAN PUBLIC INSTITUTION. ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH NEWLY DIAGNOSED OF ACUTE LYMPHOBLASTIC LEUKEMIA:COMPARATIVE RESULTS OF DIFFERENT PROTOCOLS
por: Sotomayor Duque, G., et al.
Publicado: (2022)

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h0tqoedgl539oinbf4s09c3iib